This invention relates to a pharmaceutical composition comprising antibodies that specifcally bind to folate receptor-α (FR-α), said antibodies comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and a light chain comprising the amino acid sequence comprising a single amino acid substitution relative to SEQ ID NO: 2, wherein said composition of antibodies blocks a biological activity of FR-α and induces antibody-dependent cellular cytotoxicity (ADCC) of FR-α-bearing cells, wherein the binding affinity of said composition of antibodies for FR-α is at least that corresponding to a dissociation constant of 1 x 10-8 M, and wherein said composition is free of a polypeptide consisting of amino acids 20 to 111 of SEQ ID NO: 24, for use in the treatment of folate receptor-α-expressing ovarian cancer in a patient.
